Compare Stocks: TSHA, TDUP, and PRPL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PRPL Purple Innovation	$7.16 -1.3%	$8.94	$6.12 ▼ $31.50	$31.19M	1.46	15,417 shs	3,103 shs
TDUP ThredUp	$3.15 +0.4%	$5.82	$3.04 ▼ $12.28	$408.80M	2.01	2.35 million shs	299,290 shs
TSHA Taysha Gene Therapies	$6.38 -4.6%	$6.08	$2.71 ▼ $7.30	$1.83B	1.22	2.87 million shs	581,888 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PRPL Purple Innovation	-20.33%	-25.64%	-11.69%	-36.57%	-62.95%
TDUP ThredUp	-2.79%	-49.11%	-52.42%	-25.24%	-68.09%
TSHA Taysha Gene Therapies	+4.87%	+7.74%	+5.36%	+0.15%	+142.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PRPL Purple Innovation	$7.16 -1.3%	$8.94	$6.12 ▼ $31.50	$31.19M	1.46	15,417 shs	3,103 shs
TDUP ThredUp	$3.15 +0.4%	$5.82	$3.04 ▼ $12.28	$408.80M	2.01	2.35 million shs	299,290 shs
TSHA Taysha Gene Therapies	$6.38 -4.6%	$6.08	$2.71 ▼ $7.30	$1.83B	1.22	2.87 million shs	581,888 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PRPL Purple Innovation	-20.33%	-25.64%	-11.69%	-36.57%	-62.95%
TDUP ThredUp	-2.79%	-49.11%	-52.42%	-25.24%	-68.09%
TSHA Taysha Gene Therapies	+4.87%	+7.74%	+5.36%	+0.15%	+142.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PRPL Purple Innovation	1.67	Reduce	$16.25	127.11% Upside
TDUP ThredUp	2.50	Moderate Buy	$6.55	107.87% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	100.30% Upside

Current Analyst Ratings Breakdown

Latest TSHA, TDUP, and PRPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	TDUP ThredUp	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.50
8/6/2026	TDUP ThredUp	Telsey Advisory Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $6.00
7/21/2026	TSHA Taysha Gene Therapies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
7/17/2026	PRPL Purple Innovation	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	TSHA Taysha Gene Therapies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$11.00
6/30/2026	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
6/30/2026	TSHA Taysha Gene Therapies	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$12.00 ➝ $15.00
6/24/2026	TDUP ThredUp	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	TSHA Taysha Gene Therapies	Pivotal Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
6/23/2026	TSHA Taysha Gene Therapies	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $14.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PRPL Purple Innovation	$460.28M	0.07	N/A	N/A	($6.84) per share	-1.05
TDUP ThredUp	$310.81M	1.31	N/A	N/A	$0.47 per share	6.70
TSHA Taysha Gene Therapies	$7.47M	245.20	N/A	N/A	$0.90 per share	7.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PRPL Purple Innovation	-$51.41M	-$11.24	N/A	N/A	N/A	-10.74%	N/A	-10.65%	N/A
TDUP ThredUp	-$20.21M	-$0.17	N/A	N/A	N/A	-6.65%	-37.30%	-13.03%	N/A
TSHA Taysha Gene Therapies	-$109M	-$0.38	N/A	N/A	N/A	N/A	-56.07%	-40.16%	N/A

Latest TSHA, TDUP, and PRPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/10/2026	Q2 2026	PRPL Purple Innovation	-$2.18	-$1.52	+$0.66	-$0.74	$104.39 million	$98.27 million
8/5/2026	Q2 2026	TDUP ThredUp	-$0.0298	-$0.05	-$0.0202	-$0.05	$90.34 million	$90.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PRPL Purple Innovation	N/A	N/A	N/A	N/A	N/A
TDUP ThredUp	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PRPL Purple Innovation	N/A	1.24	0.62
TDUP ThredUp	0.29	0.99	0.99
TSHA Taysha Gene Therapies	0.23	14.04	14.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PRPL Purple Innovation	88.41%
TDUP ThredUp	89.08%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
PRPL Purple Innovation	54.00%
TDUP ThredUp	23.10%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PRPL Purple Innovation	1,100	4.36 million	2.01 million	Optionable
TDUP ThredUp	2,132	129.04 million	99.23 million	Optionable
TSHA Taysha Gene Therapies	180	287.36 million	277.36 million	Optionable

TSHA, TDUP, and PRPL Headlines

Recent News About These Companies

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12 at 4:23 AM | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11 at 10:00 PM | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11 at 9:03 PM | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11 at 4:10 PM | marketbeat.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11 at 4:00 PM | globenewswire.com

Taysha Gene Therapies (TSHA) Expected to Post Quarterly Earnings on Tuesday

August 10 at 1:56 AM | americanbankingnews.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 3, 2026 | globenewswire.com

Seven Fleet Capital Management LP Has $2.80 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

August 2, 2026 | marketbeat.com

ADAR1 Capital Management LLC Has $13.32 Million Stock Position in Taysha Gene Therapies, Inc. $TSHA

July 29, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Healthcare of Ontario Pension Plan Trust Fund

July 28, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading 8% Higher - Still a Buy?

July 27, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. $TSHA Shares Acquired by Rice Hall James & Associates LLC

July 26, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. $TSHA Position Reduced by Affinity Asset Advisors LLC

July 25, 2026 | marketbeat.com

Siren L.L.C. Sells 1,300,000 Shares of Taysha Gene Therapies, Inc. $TSHA

July 24, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Buy" by Brokerages

July 24, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

July 15, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 7.4% - Still a Buy?

July 14, 2026 | marketbeat.com

Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock

July 11, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, TDUP, and PRPL Company Descriptions

Purple Innovation NASDAQ:PRPL

$7.16 -0.10 (-1.31%)

As of 10:09 AM Eastern

Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.

ThredUp NASDAQ:TDUP

$3.15 +0.01 (+0.35%)

As of 10:10 AM Eastern

ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.

Taysha Gene Therapies NASDAQ:TSHA

$6.38 -0.31 (-4.57%)

As of 10:10 AM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, TDUP, and PRPL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, TDUP, and PRPL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, TDUP, and PRPL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, TDUP, and PRPL Company Descriptions

Purple Innovation NASDAQ:PRPL

ThredUp NASDAQ:TDUP

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, TDUP, and PRPL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, TDUP, and PRPL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, TDUP, and PRPL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, TDUP, and PRPL Company Descriptions

Purple Innovation NASDAQ:PRPL

ThredUp NASDAQ:TDUP

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools